Novo Nordisk A/S (NYSE:NVO) is one of the 12 stocks that will make you rich in 10 years. On June 23, the company discontinued ...

San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...

The stock's market-beating momentum has come crashing to a halt, following shocking allegations from one of the world's ...

The partnership helps Novo capture patients who have been using compounded versions of the medicine, while allowing ...

Hims & Hers Health continues to eye personalized services and global expansion. Read more on what investors should know about ...

Semaglutide manufacturers seem to be taking advantage of America’s health crises to indulge in anticompetitive behavior.

Novo Nordisk has launched Wegovy in India, a weight-loss drug challenging Eli Lilly's Mounjaro. Available by June 2025, ...

Danish drugmaker Novo Nordisk on Tuesday launched its blockbuster weight-loss drug Wegovy in India, three months after Eli Lilly began marketing its rival product Mounjaro in the world's most populous ...

Novo Nordisk said it will stop selling Wegovy on Hims & Hers, ... to make more than $700 million this year on weight-loss services, a target that could be difficult to reach without Wegovy sales.

Shares in Denmark's pharmaceutical giant Novo Nordisk ( NVO 0.63%) were lower by 4% as of 11 a.m. ET today. The move comes as ...

Novo Nordisk ends Wegovy deal with Hims over legal issues, sending the stock tumbling. What happens next? Here's a look.